Advertisement
In this episode of Prop Personalities, we sit down with Hars...
Luxury real estate is one of the most talked-about segments ...
Welcome to Prop Personalities by Prop News Time - a podcast ...
Airports play a much bigger role than just enabling travel -...
Why does the same hotel brand operate multiple properties in...
AstraZeneca India has planned to sell its 64-acre manufacturing facility located in North Bengaluru for around INR 3,400 crore. The decision is part of a broader global restructuring exercise by its UK-based parent company, which is reviewing its manufacturing and supply network across markets. The asset sale reflects a continued focus on streamlining operations and monetising non-core infrastructure. The Bengaluru site, long associated with the company's production activities, is now being evaluated for divestment as AstraZeneca strengthens its focus on research, innovation, and digital healthcare capabilities in India and other key markets.
AstraZeneca India has decided to divest its 64-acre manufacturing facility in North Bengaluru for approximately INR 3,400 crore. The move is part of a wider global review being undertaken by its UK-based parent company, AstraZeneca Plc, which is reassessing its manufacturing and supply chain infrastructure across different regions. Advertisement
The Bengaluru asset has been a significant part of the company's manufacturing footprint in India for several years and has supported its production-related operations. However, the company is now moving towards a strategy that prioritises optimisation of global assets and reduction of non-core holdings, especially in locations where land value and redevelopment potential are high.
The planned divestment is aligned with AstraZeneca's ongoing shift in operational focus. The organisation has been increasingly concentrating on research-led and technology-driven areas such as drug development, digital health solutions, and data-based healthcare innovation. This has resulted in a gradual rebalancing of its presence in India, where manufacturing assets are being reviewed while innovation and R&D functions continue to expand.
Industry indications suggest that the Bengaluru site has been under periodic evaluation for monetisation due to its large land parcel and strategic location within a major industrial and urban growth corridor. The scale of 64 acres further adds to its commercial significance, making it a notable transaction in the corporate real estate space.
The divestment also reflects a broader trend among global pharmaceutical companies, where ownership of large manufacturing infrastructure is being reconsidered in favour of more flexible and asset-light operating models. In India, AstraZeneca has simultaneously strengthened its capabilities in research and digital healthcare, particularly through its Bengaluru innovation ecosystem, which remains a key part of its long-term strategy.
5th Jun, 2025
25th May, 2023
11th May, 2023
27th Apr, 2023
Advertisement
Facebook
Whatsapp
